Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (5y) (2014 - 2026)
Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.44% |
| Mar 31, 2026 | 1.74% |
| Dec 31, 2025 | 34.19% |
| Sep 30, 2025 | -51.54% |
| Jun 30, 2025 | -23.31% |
| Mar 31, 2025 | -23.02% |
| Dec 31, 2024 | 56.21% |
| Sep 30, 2024 | -19.59% |
| Jun 30, 2024 | -30.91% |
| Mar 31, 2024 | -82.97% |
| Dec 31, 2023 | 1.64% |
| Sep 30, 2023 | -22.77% |
| Jun 30, 2023 | 1.12% |
| Mar 31, 2023 | -37.33% |
| Dec 31, 2022 | 3.55% |
| Sep 30, 2022 | -75.51% |
| Jun 30, 2022 | 22.35% |
| Mar 31, 2022 | 19.80% |
| Dec 31, 2021 | 90.46% |
| Sep 30, 2021 | -21.54% |